09313548 PASCAL No.: 91-0103922
Cocaine abuse: historical, epidemiologic, and clinical perspectives for pediatricians
KRUG S E
Case Western Reserve uiniv. school medicine, dep. pediatrics, Cleveland OH, USA
Journal: Advances in pediatrics, 1989, 36 369-406
Language: English

4/3,AB/3 (Item 3 from file: 144)
DIALOG(R)File 144:Pascal
(c) 1994 INIST/CNRS. All rts. reserv.

09119219 PASCAL No.: 90-0287600
Heterocycles as physiological ligands for the benzodiazepine receptor and for other binding sites
WILDMANN J
Georg-August-univ., inst. biochemie, Goettingen 3400, Federal Republic of Germany
Journal: Pharmacological research, 1989, 21 (6) 673-682
Language: English
All the benzodiazepines used in *therapy* show a similar *chemical* structure. However, *depending* on particular substituents, agonistic benzodiazepines can be subdivided into groups of different *pharmacological* potency. Besides benzodiazepines, in the past years other *alkaloid* drugs, e.g. derivatives of morphine, norharmane and tetrahydronorharmane, have been isolated from animals. Some of these substances have been discussed as physiological ligands of specific neuronal binding sites

4/3,AB/4 (Item 1 from file: 351)
DIALOG(R)File 351:DERWENT WPI
(c) 1994 Derwent Info Ltd. All rts. reserv.

Nakai, or inorganic acid salts of these. The tetrahydroprotoberberine deriv. is l-or-dl-tetrahydropalmitine, stephoridine, corydaline or xilopinine. The anticholinergic agent is scopolamine hydrobromide or anisodamine hydrobromide.

USE/ADVANTAGE - The compsns. can be used for *treating* patients addicted to, e.g., opium, morphine, heroin, cocaine, marijuana, amphetamines, etc. Admin. is oral, subcutaneous intramuscular, intravenous, etc. The compsns. are non-additive, effective, fast-acting and give rise to few side-effects.

Dwg.0/1

4/3,AB/5 (Item 2 from file: 351)
DIALOG(R)File 351:DERWENT WPI
(c) 1994 Derwent Info Ltd. All rts. reserv.

009657798 WPI Acc No: 93-351350/44
XRAM Acc No: C93-155888

Synergistic anti-neoplastic *treatment* for e.g. leukaemia, carcinoma or sarcoma, etc. - comprises administering 2-halomethylidene and S-phase or M-phase specific agent, e.g. cytarabine, fluorouracil or vinblastine

Patent Assignee: (RICH) MERRELL DOW PHARM INC
Author (Inventor): SUNKARA S P
Patent Family:

CC Number	Kind	Date	Week	
WO 9320825	A1	931028	9344	(Basic)
ZA 9302455	A	931229	9406	
AU 9338131	A	931118	9410	

Priority Data (CC No Date): US 866399 (920410)
Applications (CC,No,Date): AU 9338131 (930315); WO 93US2490 (930315); ZA 932455 (930405)
Abstract (Basic): WO 9320825 A

2-Halomethylidene deriv. of formula (I) or its salt is used in conjunction with an effective neoplastic amt. of an (A) S-phase or (B) M-phase specific agent, opt. in combination with a *pharmaceutically* acceptable carrier, for use as a *pharmaceutically* active cpd., to *treat* a patient suffering from a neoplastic disease. In (I), V is O, CH2 or S; X1, X2 are H or halogen, provided that at least one of X1 or X2 is halogen; B is gp. of formulae (i)-(iii); Y1 is N, CH, CCl, CBr or CNH2; Y2, Y3 are N or CH; Y4 is H, 1-4C alkyl or alkoxy or halogen; Y5 is amino or 1-4C alkoxy and Z is halogen or NH2.

Pref. (I) is (E)-2'-deoxy-2' -fluoromethylidenecytidine (Ia), (A) is cytarabine or fluorouracil and (B) is vinblastine.

USE/ADVANTAGE - Used to *treat* neoplastic disease states, e.g., leukaemia, carcinoma (claimed). (I) are ribonucleotide reductase inhibitors with potent antiproliferative and antitumour activity. The combination of (I) and S-phase specific antineoplastic antimetabolites or M-phase specific vinca *alkaloids* provides a synergistic antineoplastic effect. *Treatment* is esp. for acute lymphoblastic, chronic lymphocytic, acute myoblastic and chronic mylocytic leukaemias, carbinomas, e.g., of the cervix, oesophagus, stomach, etc., sarcomas, e.g., oestaroma, lepoma, etc., melanomas, e.g., amelanotic, etc. and neoplasias, e.g., carcinos aroma, lymphoid tissue type, Hodgkin;s disease, etc.. (I) and (A) or (B) are co-administered in a sequential or alternate manner. Admin. is oral or parenteral. Dosage is 10-100(5-50) mg/kg/day of (I) with amt. of (A) or (B) varying, *depending* on the partic. *drug* used.

Dwg.0/0

4/3,AB/6 (Item 3 from file: 351)
DIALOG(R)File 351:DERWENT WPI
(c) 1994 Derwent Info Ltd. All rts. reserv.

009511804 WPI Acc No: 93-205340/25

EP 449247	A	911002	9140	(Basic)
DE 4010079	A	911002	9141	
CA 2039197	A	910930	9151	
DE 4010079	C	920730	9231	
JP 4221315	A	920811	9238	
EP 449247	A3	920304	9325	
EP 449247	B1	940720	9428	

Priority Data (CC No Date): DE 4010079 (900329)
Applications (CC,No,Date): EP 91104858 (910327); DE 4010079 (900329); JP 9164275 (910328); EP 91104858 (910327); EP 91104858 (910327)
Abstract (Basic): EP 449247 A

Galanthamine (I) or its acid-addn. salts are used to prepare medicaments for *treating* alcoholism.

(I) is a snowdrop *alkaloid*, e.g. described in J. Gen. Chem., 22, 1899 (1952), namely 4a,5,9,10,11,12-hexahydro -3-methoxy-11-methyl-6H- benzofuro(3a,3,2-ef) (2) benzazepin-6-ol of formula (I).

(I) is a reversible cholesterase inhibitor with a similar action to physostigmine and neostigmine, but with lower toxicity. At doses of 5 and 10 mg/kg (p.o.), it reduces alcohol consumption in ethanol-preferring rats from 6.47 and 6.30 g/kg respectively to 3.17 and 3.71 g/kg respectively, without significant affecting food and drink intake.

(I) may be formulated for transdermal, oral or parenteral admin., opt. in slow-release form. Dosages are not specified. @(7pp Dwg.No.0/0

Abstract (EP): 9428 EP 449247 B

The use of a *pharmaceutic* formulation containing galanthamine or one of the *pharmaceutically* acceptable acid addition salts thereof for the manufacture of a *pharmaceutical* product for reducing the compulsive desire (*craving*) for *alcohol* in the *treatment* of chronic alcoholism. Dwg.0/0

Abstract (DE): 9231 DE 4010079 C

Galanthamine or 3-methoxy-6-hydroxy-11 -methyl-4a,5,9,10,11,12-hexahydro-benzofuro (3a,3,2-ef)(2) benzazepine of formula (I) or its nontoxic salt is used for the *treatment* of alcoholism. Active substance is dispersed with the usual carriers and opt. additives, and is administered orally, transdermally or parenterally.

Dwg.0/0

4/3,AB/8 (Item 5 from file: 351)
DIALOG(R)File 351:DERWENT WPI

008035267 WPI Acc No: 89-300379/41
XRAM Acc No: C89-132881
XRPX Acc No: N89-229131
Alcohol *dependency* and *abuse* *treatment* - comprises administering *ibogaine* and/or its non-toxic salts
Patent Assignee: (NDAI-) NDA INT INC
Author (Inventor): LOTSOF H S
Patent Family:

CC Number	Kind	Date	Week	
US 4857523	A	890815	8941	(Basic)

Priority Data (CC No Date): US 221030 (880718)
Abstract (Basic): US 4857523

Treating *alcohol* *dependency* and *abuse* comprises internally adminstering a dosage of 4-25 mg/kg of *ibogaine* and/or its *therapeutically* active cpd.

The dosage is administered orally and the *compsn*. contains *ibogaine* and/or its hydro chloride or hydrobromide in a dosage of 400-1000 mg. The dosage is pref. in capsule, tablet, pill, powder or soln. form and is admixed with binders or fillers. A plurality of dosages are administered, intervals of a number of days intervening between successive dosages. A single *treatment* is effective for about

CC	Number	Kind	Date	Week	
EP	65747	A	821201	8249	(Basic)
DE	3218761	A	821216	8251	
JP	58023630	A	830212	8312	
ZA	8203369	A	830215	8318	
US	4444758	A	840424	8419	
US	4496545	A	850129	8507	
CA	1188989	A	850618	8529	
IL	65782	A	850830	8543	
EP	65747	B	861015	8642	
IT	1152116	B	861231	8850	
JP	91054089	B	910819	9137	
DE	3218761	C2	930506	9318	

Priority Data (CC No Date): CH 813306 (810521)

Applications (CC,No,Date): EP 82104367 (820518); DE 3218761 (820518); JP 8283370 (820519); US 379162 (790517); US 583520 (840224)

Abstract (Basic): The use of the nonapeptide (I) or its physiologically acceptable salts for *treating* *withdrawal* symptoms from *drug* addiction is new.

Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (I).

Particularly (I) is used to *treat* withdrawal from opiates (morphine or heroin) or from alcohol. It is administered intravenously or subcutaneously at a dose (for a 75 kg subject) of 1 mg, one or more times a day.

A pref. soln. for injection comprises 1 mg (I); 1 mg p-chloro-m-cresol (II); 8.9 mg NaCl and water to 1 ml. The (II) was first dissolved in some of the water (sparged with nitrogen) at 90 deg.C, then the soln. cooled and (I) and NaCl added. The soln. was made up to volume with water, sterile-filtered and filled into ampoules under aseptic conditions.

(I), 'delta sleep-inducing peptide', is already known as a hypnotic. When tested in rats and dogs at doses 50 times greater than those intended for human use, (I) caused no adverse changes to haematologicals haematochemical or urinary status, to electrocardiograms or to the histology of internal organs. (12pp

Abstract (US): 8507 US 4496545

Compsn. for *treating* addictive *drug* *withdrawal* conditions comprises 0.55-1.1 mg nonapeptide of formula:-@

Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu@

or its salt and a carrier.

The *compsn*. may also comprise 10.0 mg D-mannitol and 1.0 ml sterile water for injection. A pref. *compsn*. comprises 1.0mg of the PePtide, 1.0mg p-chloro-m-cresol, 8.9mg NaCl and 1.0ml sterile water for injection.

USE - The compsns. are well tolerated and are used for *treating* addictive conditions caused by heroin, morphine, etc.; opiates, barbiturates, methadone, cannabis and ethanol (alcoholism). @(4pp)@

8419 US 4444758

Treatment of *drug* addiction *withdrawal* symptoms and/or polytoxicomania comprises administering a nonapeptide of formula Trp-Ala-Gly-Gly-Asp- Ala-Ser-Gly-Glu or one of its nontoxic salts in effective amts., (daily dose 1.5mg. per 75kg. body wt., one or more times).

The process is applicable to addicts of opium *alkaloids* (esp. heroin and morphine), opiates, barbiturates, methadone, cannabis and alcohol. @(4pp)@

Abstract (EP): 8642 EP 65747

The use of the nonapeptide of the formula

Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu

or one of its physiologically compatible salts (*compound* 1) for the manufacture of a medicament for the *treatment* of addictive *drug* *withdrawal* conditions. @(5pp)@

Abstract (DE): 9318 DE 3218761 C

Nonapeptide of formula Trp-Ala-Gly-Asp-Ala-Ser-Gly-Glu or its nontoxic salt is the active component, dispersed with the usual carriers and opt. ac[illegible]tives, for the *treatment* of *drug* addiction

11541249 PASCAL No.: 94-0421753
Gastric antiulcer and cytoprotective effects of cathinone, a psychoactive *alkaloid* of khat (Catha edulis Forsk.) and amphetamine in rats
Towards a molecular basis in opioid research
AL-SHABANAH O A; AL-GHARABLY N M; ISLAM M W; AL-HARBI M M
NYBERG Fred, ed; POST Claes, ed; VAN REE Jan, ed; SCHULZ Rudiger, ed; TERENIUS Lars, ed
King Saud univ., coll. pharmacy, dep. pharmacology, Riyadh 11451, Saudi Arabia
Uppsala univ., dep. pharmaceutical biosci., 75185 Uppsala, Sweden
INRC : international narcotics research conference, 24 (Skoevde SWE) 1993-07-10
Journal: Regulatory peptides, 1994 (SUP1) S297-S299
Language: English

5/3/4 (Item 4 from file: 144)
DIALOG(R)File 144:Pascal
(c) 1994 INIST/CNRS. All rts. reserv.

11524211 PASCAL No.: 94-0367001
Open-label, dose run-up study of diethylpropion in initial cocaine abstinence
ALIM T N; ROSSE R B; VOCCI F J JR; DEUTSCH S I
Dep. veterans affairs medical cent., psychiatry serv., VA/NIDA res. unit, Washington DC 20422, USA
Journal: Clinical neuropharmacology, 1994, 17 (2) 175-187
Language: English

5/3/5 (Item 5 from file: 144)
DIALOG(R)File 144:Pascal
(c) 1994 INIST/CNRS. All rts. reserv.

11509807 PASCAL No.: 94-0350529
Lisuride reduces intravenous cocaine self-administration in rats
PULVIRENTI L; KOOB G F
Scripps res. inst., dep. neuropharmacology, La Jolla CA 92037, USA
Journal: Pharmacology, biochemistry and behavior, 1994, 47 (4) 819-822
Language: English

5/3/6 (Item 6 from file: 144)
DIALOG(R)File 144:Pascal
(c) 1994 INIST/CNRS. All rts. reserv.

11486405 PASCAL No.: 94-0324399
The 5-HT SUB 3 antagonist zacopride attenuates cocaine-induced increases in extracellular dopamine in rat nucleus accumbens
MCNEISH C S; SVINGOS A L; HITZEMANN R; STRECKER R E
State univ. New York Stony Brook, dep. psychiatry behavioral sci., Stony Brook NY 11794-8790, USA
Journal: Pharmacology, biochemistry and behavior, 1993, 45 (4) 759-763
Language: English

5/3/7 (Item 7 from file: 144)
DIALOG(R)File 144:Pascal
(c) 1994 INIST/CNRS. All rts. reserv.

11424023 PASCAL No.: 94-0257623
Selective antagonism of dopamine D SUB 1 and D SUB 2 receptors does not block the development of behavioral sensitization to cocaine
MATTINGLY B A; HART T C; LIM K; PERKINS C
Morehead State univ., dep. psychology, Morehead KY 40351-1689, USA

5/3/10 (Item 10 fro.. file: 144)
DIALOG(R)File 144:Pascal
(c) 1994 INIST/CNRS. All rts. reserv.

11360314 PASCAL No.: 94-0183191
Effects of the calcium antagonist isradipine on cocaine intravenous self-administration in rats
MARTELLOTTA M C; KUZMIN A; MUGLIA P; GESSA G L; FRATTA W
Univ. Cagliari, B.B. Brodie dep. neurosci., 09124 Cagliari, Italy
Journal: Psychopharmacologia, 1994, 113 (3-4) 378-380
Language: English

5/3/11 (Item 11 from file: 144)
DIALOG(R)File 144:Pascal
(c) 1994 INIST/CNRS. All rts. reserv.

11307982 PASCAL No.: 94-0128604
Persistence of the ability of amphetamine preexposure to facilitate acquisition of cocaine self-administration
VALADEZ A; SCHENK S
Texas A&M univ., dep. psychology, College Station TX 77843, USA
Journal: Pharmacology, biochemistry and behavior, 1994, 47 (1) 203-205
Language: English

5/3/12 (Item 12 from file: 144)
DIALOG(R)File 144:Pascal
(c) 1994 INIST/CNRS. All rts. reserv.

11307958 PASCAL No.: 94-0128580
Ibogaine reduces preference for cocaine consumption in C57BL/6By mice
SERSHEN H; HASHIM A; LAJTHA A
Cent. neurochemistry, N.S. Kline inst., Orangeburg NY 10962-2210, USA
Journal: Pharmacology, biochemistry and behavior, 1994, 47 (1) 13-19
Language: English

5/3/13 (Item 13 from file: 144)
DIALOG(R)File 144:Pascal
(c) 1994 INIST/CNRS. All rts. reserv.

11236289 PASCAL No.: 94-0054203
Comparison of the behavioral effects of *ibogaine* from three sources : mediation of discriminative activity
SCHECHTER M D; GORDON T L
Northeaster Ohio univ. coll. medicine, dep. pharmacology, Rootstown OH 44272-0095, USA
Journal: European journal of pharmacology, 1993, 249 (1) 79-84
Language: English

5/3/14 (Item 14 from file: 144)
DIALOG(R)File 144:Pascal
(c) 1994 INIST/CNRS. All rts. reserv.

11184773 PASCAL No.: 94-0001555
Cocaine administration prior to reactivation facilitates later acquisition of an avoidance response in rats
RODRIGUEZ W A; PHILLIPS M Y; RODRIGUEZ S B; MARTINEZ J L JR
Univ. California, dep. psychology, Berkeley CA 94720, USA
Journal: Psychopharmacologia, 1993, 112 (2-3) 366-370
Language: English

5/3/15 (Item 15 from file: 144)

5/3/18 (Item 18 from file: 144)
DIALOG(R)File 144:Pascal

10999643 PASCAL No.: 93-0509150
Expression of the multidrug transporter, P-glycoprotein, in renal and transitional cell carcinomas
NISHIYAMA K; SHIRAHAMA T; YOSHIMURA A; SUMIZAWA T; FURUKAWA T; ICHIKAWA-HARAGUCHI M; AKIYAMA S I; OHI Y
Kagoshima univ., fac. medicine, inst. cancer res., 8-35-1 Sakuragaoka, Kagoshima 890, Japan
Journal: Cancer, 1993, 71 (11) 3611-3619
Language: English

5/3/19 (Item 19 from file: 144)
DIALOG(R)File 144:Pascal

10789353 PASCAL No.: 93-0298708
Corneal complications associated with the use of crack cocaine
SACHS R; ZAGELBAUM B M; HERSH P S
Albert Einstein coll. medicine, dep. ophthalmology, Bronx NY 10467, USA
Journal: Ophthalmology : (Rochester, MN), 1993, 100 (2) 187-191
Language: English

5/3/20 (Item 20 from file: 144)
DIALOG(R)File 144:Pascal

10342414 PASCAL No.: 92-0545874
Effects of *ibogaine* on acute signs of morphine withdrawal in rats : independence from tremor
GLICK S D; ROSSMAN K; RAO N C; MAISONNEUVE I M; CARLSON J N
Albany medical coll., capital district gen. drug abuse res. treatment, dep. pharmacology, Albany NY 12208, USA
Journal: Neuropharmacology, 1992, 31 (5) 497-500
Language: English

5/3/21 (Item 21 from file: 144)
DIALOG(R)File 144:Pascal

10202375 PASCAL No.: 92-0408277
Effect of chronic cocaine *treatment* on D SUB 2 receptors regulating the release of dopamine and acetylcholine in the nucleus accumbens and striatum
GIFFORD A N; JOHNSON K M
Univ. Texas medical branch, dep. pharmacology toxicology, Galveston TX 77550, USA
Journal: Pharmacology, biochemistry and behavior, 1992, 41 (4) 841-846
Language: English

5/3/22 (Item 22 from file: 144)
DIALOG(R)File 144:Pascal

10132520 PASCAL No.: 92-0338273
The influence of chronic nicotine *treatment* on stress-induced gastric ulceration and emptying rate in rats
QIU B S; CHO C H; OGLE C W
Univ. Hong Kong, fac. medicine, dep. pharmacology, Hong Kong, Hong Kong
Journal: Experientia, 1992, 48 (4) 389-391
Language: English

Language: English

/3/24 (Item 24 from file: 144)
ALOG(R)File 144:Pascal
) 1994 INIST/CNRS. All rts. reserv.

08743484 PASCAL No.: 89-0292766
Effect of *ibogaine* on naloxone-precipitated withdrawal syndrome in
ronic morphine-dependent rats
DZOLJIC E D; KAPLAN C D; DZOLJIC M R
Erasmus univ., medical fac., dep. pharmacology, Rotterdam DR 3000,
Eherlands
Journal: Archives internationales de Pharmacodynamie et de Therapie,
88, 294 64-70
Language: English

/3/25 (Item 25 from file: 144)
ALOG(R)File 144:Pascal
) 1994 INIST/CNRS. All rts. reserv.

03614493 PASCAL No.: 82-0128557
TOLFENAMIC ACID AND ERGOTAMINE ABUSE
ALA-HURULA V; MYLLYLA V V; HOKKANEN E; TOKOLA O
UNIV. CENT. HOSP. OULU/OULU,FINLAND
Journal: HEADACHE, 1981, 21 (6) 240-242
Language: ENGLISH

/3/26 (Item 26 from file: 144)
ALOG(R)File 144:Pascal
) 1994 INIST/CNRS. All rts. reserv.

02062457 PASCAL No.: 78-0409456
PEYOTL, A POTENTIAL ETHNOPHARMACOLOGIC AGENT FOR *ALCOHOLISM* AND OTHER
RUG* *DEPENDENCIES*: POSSIBLE BIOCHEMICAL RATIONALE.
BLUM K; FUTTERMAN S L; PASCAROSA P
UNIV. TEXAS HEALTH SCI. CENT., SAN ANTONIO,TEX. 78284
Journal: CLIN. TOXICOL., 1977, 11 (4) 459-472
Language: ENGLISH

/3/27 (Item 1 from file: 350)
ALOG(R)File 350:Derwent World Pat.
) 1994 Derwent Info Ltd. All rts. reserv.

1376057 WPI Acc No: 75-25708W/15
AM Acc No: C75-W25708
Glucose-6-phosphate dehydrogenase conjugated drugs - useful for enzyme
immunoassays
tent Assignee: (SYNT) SYVA CO
tent Family:
CC Number Kind Date Week
US 3875011 A 750401 7515 (Basic)
iority Data (CC No Date): US 438890 (740201); US 143609 (710514); US
304157 (721106)

/3/28 (Item 1 from file: 351)
ALOG(R)File 351:DERWENT WPI
) 1994 Derwent Info Ltd. All rts. reserv.

9794530 WPI Acc No: 94-074383/09
AM Acc No: C94-033856
Treatment of *narcotic* *withdrawal* symptoms - with Aconitum

US 5290784 A 940301 9409 (Basic)

iority Data (CC No Date): CN 91104811 (910718)
plications (CC,No,Date): US 912791 (920713)

5/3/29 (Item 2 from file: 351)
ALOG(R)File 351:DERWENT WPI
) 1994 Derwent Info Ltd. All rts. reserv.

08879922 WPI Acc No: 92-007193/01
AM Acc No: C92-003067
Treatment of poly- drug* *dependency* - with bogaine*, ibogamine or tabernanthine or their salts or deriv.; *ALKALOID*
tent Assignee: (NDAI-) NDA INT INC; (LOTS/) LOTSOF H S
thor (Inventor): LOTSOF H S
tent Family:

CC	Number	Kind	Date	Week	
WO	9118609	A	911212	9201	(Basic)
US	5152994	A	921006	9243	
EP	511325	A1	921104	9245	

iority Data (CC No Date): US 531100 (900531)
plications (CC,No,Date): EP 91910992 (910530); WO 91US3781 (910530)

5/3/30 (Item 3 from file: 351)
ALOG(R)File 351:DERWENT WPI
) 1994 Derwent Info Ltd. All rts. reserv.

04808190 WPI Acc No: 86-311531/47
lated WPI Accession(s): 83-27318K
AM Acc No: C86-134925
Preventing *dependence* on psycho-active *drugs* e.g. narcotics by admin. of hapten conjugate of drug with macromolecule, e.g. serum albumin; HAPTEN
tent Assignee: (STRA/) STRAHILEVITZ M
thor (Inventor): STRAHILEVI M
tent Family:

CC	Number	Kind	Date	Week	
US	4620977	A	861104	8647	(Basic)

iority Data (CC No Date): US 319238 (811109); GB 7116001 (710520)

5/3/31 (Item 4 from file: 351)
ALOG(R)File 351:DERWENT WPI
) 1994 Derwent Info Ltd. All rts. reserv.

03850067 WPI Acc No: 83-846318/51
AM Acc No: C83-123508
Dynorphin amide analogues useful for potentiating narcotic and peptide analgesics and *treating* *narcotic* *withdrawal*
tent Assignee: (REGC) UNIV OF CALIFORNIA; (REGC) UNIV CALIFORNIA
thor (Inventor): LEE N M; LOH H H; CHANG J K
tent Family:

CC	Number	Kind	Date	Week	
EP	96592	A	831221	8351	(Basic)
AU	8314489	A	831215	8406	
NO	8302107	A	840102	8408	
FI	8302095	A	840131	8411	
DK	8302626	A	840130	8411	
JP	59025365	A	840209	8412	
ZA	8304189	A	840118	8413	
HU	T30731	T	840328	8420	
PT	76860	A	840529	8427	
US	4462941	A	840731	8433	

5/3/32 (Item 5 from file: 351)
DIALOG(R)File 351:DERWENT WPI

003459051 WPI Acc No: 82-09305J/50
XRAM Acc No: C82-J09305
Accurate hapten determn. in biological samples by competitive assay for sites on antibodies
Patent Assignee: (ELEC-) ELECTRO-NUCLEONICS; (ONEI/) O'NEILL S
Author (Inventor): O'NEILL S; WU J
Patent Family:

CC	Number	Kind	Date	Week	
WO	8204323	A	821209	8250	(Basic)
AU	8287347	A	821221	8310	
EP	79962	A	830601	8323	
JP	58500874	W	830526	8327	
DK	8300394	A	830627	8332	
FI	8300311	A	830930	8345	
EP	79962	B	850828	8535	
CA	1192490	A	850827	8539	
DE	3265823	G	851003	8541	
US	4604365	A	860805	8634	
IT	1198374	B	881221	9114	

Priority Data (CC No Date): US 269727 (810602); WO 82US737 (820528); US 406762 (820701)
Applications (CC,No,Date): EP 82902274 (820528)
?log y
30sep94 11:25:35 User219783 Session D701.3